In ALS, the intrathecal delivery of BDNF showed tolerance but inconclusive efficacy in clinical trials, while VEGF significantly delayed disease progression and preserved motor and neurological functions in murine models. Here, BDNF is linked to amyotrophic lateral sclerosis.